Belite Bio Wins Nasdaq Global Select Listing, Trading Starts Oct. 19

Belite Bio, Inc. has received approval from Nasdaq to transfer its listing from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading under the ticker symbol 'BLTE' will begin on October 19, 2026. The company focuses on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs.